IDEXX LABORATORIES INC /DE Sales Revenue, Services, Net (Deprecated 2018-01-31)
IDEXX LABORATORIES INC /DE (IDXX) reported Sales Revenue, Services, Net (Deprecated 2018-01-31) of $792.94 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-16.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueServicesNet · last filed 2018-02-16
- IDEXX LABORATORIES INC /DE sales revenue, services, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $197.09M, a 14.39% increase year-over-year.
- IDEXX LABORATORIES INC /DE sales revenue, services, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $200.94M, a 10.42% increase year-over-year.
- IDEXX LABORATORIES INC /DE sales revenue, services, net (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $204.85M, a 12.75% increase year-over-year.
- IDEXX LABORATORIES INC /DE sales revenue, services, net (deprecated 2018-01-31) for the quarter ending 2017-03-31 was $190.06M, a 12.80% increase year-over-year.
- IDEXX LABORATORIES INC /DE sales revenue, services, net (deprecated 2018-01-31) for fiscal 2017 was $792.94M, a 12.56% increase from fiscal 2016.
- IDEXX LABORATORIES INC /DE sales revenue, services, net (deprecated 2018-01-31) for fiscal 2016 was $704.45M, a 12.36% increase from fiscal 2015.
- IDEXX LABORATORIES INC /DE sales revenue, services, net (deprecated 2018-01-31) for fiscal 2015 was $626.96M, a 6.92% increase from fiscal 2014.
- IDEXX LABORATORIES INC /DE sales revenue, services, net (deprecated 2018-01-31) for fiscal 2014 was $586.39M, a 12.22% increase from fiscal 2013.
| Period end | Sales Revenue, Services, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Services, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Services, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Services, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2017-12-31 | $197.09M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | $398.04M derived: sum of 2 quarters · filed 2018-02-16 | $602.89M derived: sum of 3 quarters · filed 2018-02-16 | $792.94M 10-K · filed 2018-02-16 |
| 2017-09-30 | $200.94M 10-Q · filed 2017-10-31 | $405.79M derived: sum of 2 quarters · filed 2017-10-31 | $595.85M 10-Q · filed 2017-10-31 | $768.15M derived: sum of 4 quarters · filed 2018-02-16 |
| 2017-06-30 | $204.85M 10-Q · filed 2017-08-01 | $394.90M 10-Q · filed 2017-08-01 | $567.20M derived: sum of 3 quarters · filed 2018-02-16 | $749.19M derived: sum of 4 quarters · filed 2018-02-16 |
| 2017-03-31 | $190.06M 10-Q · filed 2017-04-28 | $362.35M derived: sum of 2 quarters · filed 2018-02-16 | $544.34M derived: sum of 3 quarters · filed 2018-02-16 | $726.02M derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-12-31 | $172.30M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | $354.28M derived: sum of 2 quarters · filed 2018-02-16 | $535.97M derived: sum of 3 quarters · filed 2018-02-16 | $704.45M 10-K · filed 2018-02-16 |
| 2016-09-30 | $181.99M 10-Q · filed 2017-10-31 | $363.67M derived: sum of 2 quarters · filed 2017-10-31 | $532.15M 10-Q · filed 2017-10-31 | $686.97M derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-06-30 | $181.68M 10-Q · filed 2017-08-01 | $350.17M 10-Q · filed 2017-08-01 | $504.98M derived: sum of 3 quarters · filed 2018-02-16 | $664.62M derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-03-31 | $168.49M 10-Q · filed 2017-04-28 | $323.30M derived: sum of 2 quarters · filed 2018-02-16 | $482.94M derived: sum of 3 quarters · filed 2018-02-16 | $645.07M derived: sum of 4 quarters · filed 2018-02-16 |
| 2015-12-31 | $154.81M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | $314.45M derived: sum of 2 quarters · filed 2018-02-16 | $476.58M derived: sum of 3 quarters · filed 2018-02-16 | $626.96M 10-K · filed 2018-02-16 |
| 2015-09-30 | $159.64M 10-Q · filed 2016-11-01 | $321.77M derived: sum of 2 quarters · filed 2016-11-01 | $472.14M 10-Q · filed 2016-11-01 | $615.26M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-06-30 | $162.13M 10-Q · filed 2016-08-02 | $312.51M 10-Q · filed 2016-08-02 | $455.63M derived: sum of 3 quarters · filed 2017-02-17 | $605.48M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-03-31 | $150.37M 10-Q · filed 2016-04-29 | $293.49M derived: sum of 2 quarters · filed 2017-02-17 | $443.35M derived: sum of 3 quarters · filed 2017-02-17 | $595.96M derived: sum of 4 quarters · filed 2017-02-17 |
| 2014-12-31 | $143.12M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $292.98M derived: sum of 2 quarters · filed 2017-02-17 | $445.58M derived: sum of 3 quarters · filed 2017-02-17 | $586.39M 10-K · filed 2017-02-17 |
| 2014-09-30 | $149.86M 10-Q · filed 2015-10-28 | $302.46M derived: sum of 2 quarters · filed 2015-10-28 | $443.27M 10-Q · filed 2015-10-28 | $572.60M derived: sum of 4 quarters · filed 2016-02-17 |
| 2014-06-30 | $152.61M 10-Q · filed 2015-07-30 | $293.42M 10-Q · filed 2015-07-30 | $422.74M derived: sum of 3 quarters · filed 2016-02-17 | $554.35M derived: sum of 4 quarters · filed 2016-02-17 |
| 2014-03-31 | $140.81M 10-Q · filed 2015-04-28 | $270.13M derived: sum of 2 quarters · filed 2016-02-17 | $401.74M derived: sum of 3 quarters · filed 2016-02-17 | $537.00M derived: sum of 4 quarters · filed 2016-02-17 |
| 2013-12-31 | $129.32M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-17 | $260.93M derived: sum of 2 quarters · filed 2016-02-17 | $396.19M derived: sum of 3 quarters · filed 2016-02-17 | $522.53M 10-K · filed 2016-02-17 |
| 2013-09-30 | $131.60M 10-Q · filed 2014-10-24 | $266.87M derived: sum of 2 quarters · filed 2014-10-24 | $393.20M 10-Q · filed 2014-10-24 | $509.04M derived: sum of 4 quarters · filed 2015-02-17 |
| 2013-06-30 | $135.26M 10-Q · filed 2014-07-25 | $261.60M 10-Q · filed 2014-07-25 | $377.43M derived: sum of 3 quarters · filed 2015-02-17 | $496.01M derived: sum of 4 quarters · filed 2015-02-17 |
| 2013-03-31 | $126.34M 10-Q · filed 2014-04-25 | $242.17M derived: sum of 2 quarters · filed 2015-02-17 | $360.75M derived: sum of 3 quarters · filed 2015-02-17 | $484.18M derived: sum of 4 quarters · filed 2015-02-17 |
| 2012-12-31 | $115.83M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-17 | $234.41M derived: sum of 2 quarters · filed 2015-02-17 | $357.84M derived: sum of 3 quarters · filed 2015-02-17 | $476.35M 10-K · filed 2015-02-17 |
| 2012-09-30 | $118.58M 10-Q · filed 2013-10-22 | $242.00M derived: sum of 2 quarters · filed 2013-10-22 | $360.51M 10-Q · filed 2013-10-22 | $468.28M derived: sum of 4 quarters · filed 2014-02-18 |
| 2012-06-30 | $123.43M 10-Q · filed 2013-07-23 | $241.94M 10-Q · filed 2013-07-23 | $349.70M derived: sum of 3 quarters · filed 2014-02-18 | $459.32M derived: sum of 4 quarters · filed 2014-02-18 |
| 2012-03-31 | $118.51M 10-Q · filed 2013-04-23 | $226.28M derived: sum of 2 quarters · filed 2014-02-18 | $335.90M derived: sum of 3 quarters · filed 2014-02-18 | $450.26M derived: sum of 4 quarters · filed 2014-02-18 |
| 2011-12-31 | $107.77M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-18 | $217.39M derived: sum of 2 quarters · filed 2014-02-18 | $331.75M derived: sum of 3 quarters · filed 2014-02-18 | $436.04M 10-K · filed 2014-02-18 |
| 2011-09-30 | $109.62M 10-Q · filed 2012-10-19 | $223.98M derived: sum of 2 quarters · filed 2012-10-19 | $328.27M 10-Q · filed 2012-10-19 | $423.79M derived: sum of 4 quarters · filed 2013-02-19 |
| 2011-06-30 | $114.36M 10-Q · filed 2012-07-20 | $218.65M 10-Q · filed 2012-07-20 | $314.17M derived: sum of 3 quarters · filed 2013-02-19 | $410.50M derived: sum of 4 quarters · filed 2013-02-19 |
| 2011-03-31 | $104.29M 10-Q · filed 2012-04-20 | $199.81M derived: sum of 2 quarters · filed 2013-02-19 | $296.14M derived: sum of 3 quarters · filed 2013-02-19 | $397.81M derived: sum of 4 quarters · filed 2013-02-19 |
| 2010-12-31 | $95.52M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-19 | $191.85M derived: sum of 2 quarters · filed 2013-02-19 | $293.52M derived: sum of 3 quarters · filed 2013-02-19 | $385.29M 10-K · filed 2013-02-19 |
| 2010-09-30 | $96.33M 10-Q · filed 2011-10-21 | $198.00M derived: sum of 2 quarters · filed 2011-10-21 | $289.76M 10-Q · filed 2011-10-21 | $376.58M derived: sum of 4 quarters · filed 2012-02-17 |
| 2010-06-30 | $101.67M 10-Q · filed 2011-07-22 | $193.43M 10-Q · filed 2011-07-22 | $280.25M derived: sum of 3 quarters · filed 2012-02-17 | $367.84M derived: sum of 4 quarters · filed 2012-02-17 |
| 2010-03-31 | $91.76M 10-Q · filed 2011-04-21 | $178.58M derived: sum of 2 quarters · filed 2012-02-17 | $266.17M derived: sum of 3 quarters · filed 2012-02-17 | $355.83M derived: sum of 4 quarters · filed 2012-02-17 |
| 2009-12-31 | $86.81M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-17 | $174.41M derived: sum of 2 quarters · filed 2012-02-17 | $264.06M derived: sum of 3 quarters · filed 2012-02-17 | $344.62M 10-K · filed 2012-02-17 |
| 2009-09-30 | $87.59M 10-Q · filed 2010-10-22 | $177.25M derived: sum of 2 quarters · filed 2010-10-22 | $257.81M 10-Q · filed 2010-10-22 | |
| 2009-06-30 | $89.66M 10-Q · filed 2010-07-23 | $170.22M 10-Q · filed 2010-07-23 | ||
| 2008-12-31 | $330.71M 10-K · filed 2011-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | United States | $6.510B | 26.31 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |